<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEPTAZANE- methazolamideÂ tabletÂ </strong><br>Paddock Laboratories, LLC<br></p></div>
<h1>
<span class="Bold">NEPTAZANE</span>Â® <span class="Bold">Methazolamide</span><span class="Bold"> Tablets USP 25 mg and 50 mg</span><br><span class="Bold">Rx Only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_0f96f7da-88b9-43b4-8334-26116ca0bf28"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Methazolamide, a sulfonamide derivative, is a white crystalline powder, weakly acidic, slightly soluble in water, alcohol and acetone.</p>
<p>The chemical name for methazolamide is: N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-acetamide and it has the following structural formula:</p>
<div class="Figure">
<a name="id2105527676"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7731560b-dbe7-4912-814e-ef60629e5f07&amp;name=7731560b-dbe7-4912-814e-ef60629e5f07-01.jpg">
</div>
<p>Each tablet, for oral administration, contains 25 mg or 50 mg methazolamide. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate (powder), and microcrystalline cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_90b26c2a-9f5f-4f26-941f-26f9dd17acd1"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Methazolamide is a potent inhibitor of carbonic anhydrase.</p>
<p>Methazolamide is well absorbed from the gastrointestinal tract. Peak plasma concentrations are observed 1 to 2 hours after dosing. In a multiple-dose, pharmacokinetic study, administration of methazolamide 25 mg bid, 50 mg bid, and 100 mg bid demonstrated a linear relationship between plasma methazolamide levels and methazolamide dose. Peak plasma concentrations (Cmax) for the 25 mg, 50 mg and 100 mg bid regimens were 2.5 mcg/mL, 5.1 mcg/mL, and 10.7 mcg/mL, respectively. The area under the plasma concentrationtime curves (AUC) was 1130 mcg.min/mL, 2571 mcg.min/mL, and 5418 mcg.min/mL for the 25 mg, 50 mg, and 100 mg dosage regimens, respectively.</p>
<p>Methazolamide is distributed throughout the body including the plasma, cerebrospinal fluid, aqueous humor of the eye, red blood cells, bile and extracellular fluid. The mean apparent volume of distribution (Varea/F) ranges from 17 L to 23 L. Approximately 55% is bound to plasma proteins. The steady-state methazolamide red blood cell:plasma ratio varies with dose and was found to be 27:1, 16:1, and 10:1 following the administration of methazolamide 25 mg bid, 50 mg bid, and 100 mg bid, respectively.</p>
<p>The mean steady-state plasma elimination half-life for methazolamide is approximately 14 hours. At steady-state, approximately 25% of the dose is recovered unchanged in the urine over the dosing interval. Renal clearance accounts for 20% to 25% of the total clearance of drug. After repeated bid-tid dosing, methazolamide accumulates to steady-state concentrations in 7 days.</p>
<p>Methazolamideâ€™s inhibitory action on carbonic anhydrase decreases the secretion of aqueous humor and results in a decrease in intraocular pressure. The onset of the decrease in intraocular pressure generally occurs within 2 to 4 hours, has a peak effect in 6 to 8 hours and a total duration of 10 to 18 hours.</p>
<p>Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not considered an effective anticonvulsant.</p>
<p>Methazolamide has a weak and transient <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span>; therefore, use results in an increase in urinary volume, with excretion of sodium, potassium, and chloride. The drug should not be used as a diuretic. Inhibition of renal <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> reabsorption produces an alkaline urine. Plasma <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> decreases, and a relative, transient <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may occur due to a disequilibrium in <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> transport in the red blood cell. Urinary citrate excretion is decreased by approximately 40% after doses of 100 mg every 8 hours. Uric acid output has been shown to decrease 36% in the first 24 hour period.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_06fc0ea5-6c3b-429d-a9a6-9a7388d114c0"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">NEPTAZANEÂ® is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, secondary <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and preoperatively in acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> where lowering the intraocular pressure is desired before surgery.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_57c8e09a-7657-4f52-ab0e-ce7046b9ee3f"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Methazolamide therapy is contraindicated in situations in which sodium and/or potassium serum levels are depressed, in cases of marked kidney or liver disease or dysfunction, in adrenal gland failure, and in <span class="product-label-link" type="condition" conceptid="4108257" conceptname="Metabolic acidosis, NAG, acidifying salts">hyperchloremic acidosis</span>. In patients with cirrhosis, use may precipitate the development of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.</p>
<p>Long-term administration of methazolamide is contraindicated in patients with angleclosure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, since organic closure of the angle may occur in spite of lowered intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_4cad5776-7b96-443b-905d-5b4db1330fb3"></a><a name="section-5"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may recur when a sulfonamide is readministered, irrespective of the route of administration.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or other serious reactions occur, the use of this drug should be discontinued.</p>
<p>Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_c4bd5b00-262a-4aef-80fb-ef8040ca45fe"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_2a5f84d3-d67e-4674-b415-5aece4286530"></a><a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">Potassium excretion is increased initially upon administration of methazolamide and in patients with cirrhosis or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> could precipitate a <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>In patients with pulmonary obstruction or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, where alveolar ventilation may be impaired, methazolamide should be used with caution because it may precipitate or aggravate <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_8c41bf99-cd3f-4dd8-9ffd-3cac630ae943"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Adverse reactions common to all sulfonamide derivatives may occur: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. Precaution is advised for early detection of such reactions, and the drug should be discontinued and appropriate therapy instituted.</p>
<p>Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="ID_82a521c8-8e89-4473-b3bc-32af130732dc"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests:</h2>
<p class="First">To monitor for hematologic reactions common to all sulfonamides, it is recommended that a baseline CBC and platelet count be obtained on patients prior to initiating methazolamide therapy and at regular intervals during therapy. If significant changes occur, early discontinuance and institution of appropriate therapy are important. Periodic monitoring of serum electrolytes is also recommended.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_51c88a25-176c-434f-88c6-7d265087472e"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors (see <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_0601c7dc-f8b8-465e-b6e3-ce4a71f668ba"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of methazolamide and its effect on fertility have not been conducted. Methazolamide was not mutagenic in the Ames bacterial test.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_3582a99c-f24f-4c60-b772-a8eaacd2a5d6"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_78ca3d8b-48b6-48b3-b628-7ef264b49567"></a><a name="section-6.6.1"></a><p></p>
<h3>Teratorgenic Effects</h3>
<div class="Section">
<a name="ID_a0900971-451e-4fa3-9476-a655a197c65b"></a><a name="section-6.6.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Methazolamide has been shown to be teratogenic (skeletal anomalies) in rats when given in doses approximately 40 times the human dose. There are no adequate and well controlled studies in pregnant women. Methazolamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_79e3e272-c876-4e13-8f07-886ac0bbd20d"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from methazolamide, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_558e5aff-6f06-40b3-a19b-6a49acc471ec"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">The safety and effectiveness of methazolamide in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_53cc3689-52f7-4fd5-8b37-5d9a7591a7bb"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions, occurring most often early in therapy, include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, particularly a â€œtinglingâ€? feeling in the extremities; hearing dysfunction or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; loss of appetite; <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>; <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>; and occasional instances of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may occur.</p>
<p>Transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> has been reported. This condition invariably subsides upon diminution or discontinuance of the medication.</p>
<p>Other occasional adverse reactions include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculi</span>. Also see <span class="Bold">PRECAUTIONS: Information for Patients </span>for possible reactions common to sulfonamide derivatives. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (see <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_e4fed5d1-d3a1-4317-a308-9ac5f82ae71a"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">No data is available regarding methazolamide overdosage in humans as no cases of acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with this drug have been reported. Animal data suggest that even a high dose of methazolamide is nontoxic. No specific antidote is known. Treatment should be symptomatic and supportive.</p>
<p><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span>, development of an acidotic state, and central nervous system effects might be expected to occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Supportive measures may be required to restore electrolyte and pH balance.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_59fc0bf8-caf4-4f9d-914a-f86ffd26f99a"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">The effective therapeutic dose administered varies from 50 mg to 100 mg two or three times daily. The drug may be used concomitantly with miotic and osmotic agents.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_f0177693-469c-4a13-9b4f-1cc4af2531e4"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">NEPTAZANEÂ® (methazolamide tablets USP, 25 mg) are round, white tablets, debossed â€œEFFâ€? on one side and â€œ21â€? on the other side and are supplied in bottles of 90, NDC 0574-<span class="Bold">0786</span>-90.</p>
<p>NEPTAZANEÂ® (methazolamide tablets USP, 50 mg) are round, white, scored tablets debossed â€œEFFâ€? on one side and â€œ20â€? on the other side and are supplied in bottles of 90, NDC 0574-<span class="Bold">0787</span>-90.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).</p>
<p>Rx Only</p>
<p>Manufactured for Perrigo</p>
<p>Minneapolis, MN 55427</p>
<p>Code 617N00</p>
<p>Rev 04-14 A</p>
<p>6V400 RC J1</p>
<p>NeptazaneÂ® is a registered trademark of Perrigo Company</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_9fc1acc9-73ae-438c-8dcf-4847a8c7c619"></a><a name="section-11"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL â€“ 25 mg Label</h1>
<p class="First">Rx Only</p>
<p>NDC 0574-0786-90</p>
<p>NeptazaneÂ®</p>
<p>Methazolamide Tablets, USP 25 mg</p>
<p> 90 Tablets</p>
<div class="Figure">
<a name="id-1595238858"></a><img alt="Neptazane(R) Methazolamide Tablets, USP 25 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7731560b-dbe7-4912-814e-ef60629e5f07&amp;name=7731560b-dbe7-4912-814e-ef60629e5f07-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0957cf86-daa4-49ba-b50c-c15312a21704"></a><a name="section-12"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL â€“ 50 mg Label</h1>
<p class="First">Rx Only</p>
<p>NDC 0574-0787-90</p>
<p>NeptazaneÂ®</p>
<p>Methazolamide Tablets, USP 50 mg</p>
<p> 90 Tablets</p>
<div class="Figure">
<a name="id-1572032717"></a><img alt="Neptazane(R) Methazolamide Tablets, USP 50 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7731560b-dbe7-4912-814e-ef60629e5f07&amp;name=7731560b-dbe7-4912-814e-ef60629e5f07-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEPTAZANEÂ 		
					</strong><br><span class="contentTableReg">methazolamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0574-0786</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHAZOLAMIDE</strong> (METHAZOLAMIDE) </td>
<td class="formItem">METHAZOLAMIDE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">EFF;21</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0574-0786-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040062</td>
<td class="formItem">01/12/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEPTAZANEÂ 		
					</strong><br><span class="contentTableReg">methazolamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0574-0787</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHAZOLAMIDE</strong> (METHAZOLAMIDE) </td>
<td class="formItem">METHAZOLAMIDE</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">EFF;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0574-0787-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040062</td>
<td class="formItem">01/12/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Paddock Laboratories, LLC
							(967694121)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7731560b-dbe7-4912-814e-ef60629e5f07</div>
<div>Set id: 7731560b-dbe7-4912-814e-ef60629e5f07</div>
<div>Version: 1</div>
<div>Effective Time: 20150127</div>
</div>
</div>Â <div class="DistributorName">Paddock Laboratories, LLC</div></p>
</body></html>
